PHARMAC proposal open for feedback

2 November 2017

PHARMAC is proposing three key changes: fund Pfizer Pregabalin; fund Apo-Gabapentin; and remove current restrictions for gabapentin.

These pain medications are anti-convulsant agents which mimic gamma-aminobutyric acid, an amino acid that inhibits nerve impulses in the body. They are used in the treatment of seizure control in some forms of epilepsy and for neuropathic pain.

Pregabalin is currently not funded. Gabapentin is currently funded subject to Special Authority and hospital restrictions. The proposal from PHARMAC is to fund Pfizer New Zealand Ltd’s brand of pregabalin (Pregabalin Pfizer) as a sole supplier, to fund Apo-Gabapentin as a sole supplier and to remove the current funding restrictions for gabapentin with a condition that would prevent funded concurrent use of both these products together

This proposal is open to feedback until 4pm on 10 November 2017.

Full PHARMAC Proposal

If you wish to provide feedback:

All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.